Aurora Cannabis rejected Curaleaf Holdings' latest takeover proposal, but the Canadian producer's board made clear it's open to hearing from other potential acquirers.
The Edmonton-based company's board of directors unanimously turned down Curaleaf's revised offer, according to a statement released Thursday. Aurora's leadership said the proposal "significantly undervalues" the company and fails to reflect its strategic position in the evolving North American cannabis market.
"After careful consideration with our financial and legal advisors, we have concluded that this offer does not represent the best path forward for Aurora or our shareholders," said Miguel Martin, Aurora's CEO. The company's board added it "remains open to evaluating proposals that appropriately recognize Aurora's value."
This marks the second time Aurora has rebuffed an approach from Curaleaf, the largest U.S. multi-state operator by revenue. Curaleaf first made its interest known in December, proposing an all-stock transaction that would have created one of the largest vertically integrated cannabis companies in North America.
The Numbers
Aurora Cannabis reported CA$72.1 million in net revenue for its most recent quarter, with the company maintaining profitability on an adjusted EBITDA basis. The Canadian LP has focused on streamlining operations and reducing debt following years of aggressive expansion that left it overleveraged.
Curaleaf, meanwhile, posted $333 million in revenue for its latest quarter. The Massachusetts-based MSO operates 152 dispensaries across 17 states and has been vocal about seeking strategic combinations as the U.S. cannabis industry consolidates.
Financial analysts have speculated about the potential deal structure and valuation. Aurora's market capitalization hovers around $500 million, while Curaleaf is valued at approximately $3.2 billion. But cross-border M&A in cannabis remains complicated by federal prohibition in the United States.
Industry Response
The rejection comes as Canadian licensed producers face mounting pressure from declining domestic cannabis prices and saturated provincial markets. Many analysts view international expansion and potential U.S. market entry as critical growth drivers for Canadian companies.
"Aurora is essentially saying they're for sale, just not to Curaleaf at this price," said Emily Paxhia, co-founder of Poseidon Investment Management. "This opens the door for other MSOs or even institutional investors to make a run at them."
Several large U.S. operators have the financial capacity to pursue Aurora, including Trulieve Cannabis, Green Thumb Industries, and Verano Holdings. But any deal would need to navigate complex regulatory requirements, particularly around U.S. federal cannabis laws and Canadian securities regulations.
Some industry observers questioned whether Aurora's board is simply playing hardball to extract a higher offer from Curaleaf. The Florida-based company has not publicly disclosed the terms of either proposal, making it difficult to assess whether Aurora's valuation expectations are realistic.
What's Next
Aurora's statement suggested the company is actively engaged with its advisors to "evaluate all strategic alternatives." That language typically signals a formal process may be underway, potentially including a broader solicitation of interest from qualified buyers.
The timing coincides with broader consolidation trends in cannabis. U.S. rescheduling discussions and potential federal reform have intensified M&A activity, with companies positioning for a post-prohibition landscape.
Curaleaf has not commented on whether it will return with a third offer. The company's executive chairman, Boris Jordan, has previously described Aurora as an attractive target that would provide manufacturing capabilities and international market access.
For Aurora, the calculus involves balancing immediate shareholder value against long-term strategic positioning. The company has invested heavily in European medical cannabis markets and maintains significant production capacity that could prove valuable as global markets mature.
Investors will watch closely to see whether Aurora's board receives competing bids in coming weeks, or whether this amounts to a negotiating tactic aimed at Curaleaf.
This article is based on original reporting by mjbizdaily.com.
